In mantle cell lymphoma, whether 18F-FDG PET/CT or flow cytometry provide superior diagnostic performance compared to biopsy in the determination of bone marrow involvement and enhance prognostic predictive value.
Combining imaging and blood tests—rather than replacing biopsy—provides the most complete picture for staging lymphoma and predicting patient outcomes.
This review compares FDG-PET/CT and flow cytometry to biopsy for assessing bone marrow involvement in mantle cell lymphoma, informing staging and prognostic workup practices. Results support integrating complementary methods rather than replacing biopsy in MCL staging.
What the study was
- Study design
- Systematic review / comparative review
- Population
- Mantle cell lymphoma patients undergoing staging
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Annals of hematology
Why it surfaced
Informative comparative review for MCL staging relevant to hematology watchlist; moderate clinical impact as it compares existing modalities without a new technology or RCT-level evidence.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.